Nuformix PLC NXP002 Update (2044Q)
27 June 2022 - 4:00PM
UK Regulatory
TIDMNFX
RNS Number : 2044Q
Nuformix PLC
27 June 2022
27 June 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
NXP002 Update
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to provide an update in relation to the
Company's NXP002 asset, a new form of tranilast and a potential
novel inhaled treatment for Idiopathic Pulmonary Fibrosis
("IPF").
The Company has previously generated positive data on NXP002,
demonstrating that:
- NXP002 can be formulated in a simple and stable solution
suitable for inhaled delivery via nebulisation;
- NXP002 formulations for nebulisation can be efficiently delivered to the lung; and
- NXP002 can dose-dependently regulate the production of
mediators relevant to lung fibrosis and inflammation following a
lipopolysaccharide (" LPS") challenge.
However, a s announced on 30 May 2022, no conclusions could be
drawn from an additional study undertaken to investigate the
duration of action of NXP002 formulations.
The Company has now initiated further studies as it continues to
generate a robust pre-clinical data package to support the
progression of NXP002, both in terms of product development and
business development discussions. These studies will directly
address issues faced in the duration of action studies. Firstly,
the Company will investigate a new formulation of NXP002 for
inhalation, delivered using an alternative method designed to
ensure consistent and controlled exposure is achieved. Secondly,
the Company will explore a new range of doses to best optimise
efficacy of treatment.
The eventual aim of the studies is to confirm the formulation's
positive pharmacological profile towards the treatment of lung
fibrosis and inflammation via inhalation and to assess its duration
of action. The studies will begin in August 2022 with results
generated throughout H2 2022 as development milestones are
achieved. Data from these inhalation studies will add to the
Company's current compelling pre-clinical dataset, to best support
the development of NXP002 as a treatment for IPF and potentially
other poorly treated fibrosing interstitial lung diseases. Further
updates will be announced in due course, as appropriate .
Commenting, Dr Julian Gilbert, Non-executive Director of
Nuformix, said: " NXP002 is our lead programme and after the
frustrations of the study undertaken earlier this year from which
no conclusions could be drawn, I am pleased that we are back on
track to investigate the product opportunity further. The planned
programme of studies is intended to ensure we have a robust
pre-clinical data package for NXP002 to support the further
progression of this asset. I look forward to providing further
updates in due course as we progress."
Enquiries:
Nuformix plc
Dr Julian Gilbert, Non-executive Via IFC Advisory
Director
Maddy Kennedy, Non-executive Director
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
About Fibrosis
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Whilst fibrosis treatments are in their infancy the
emerging lung fibrosis market demonstrates their blockbuster
potential. Idiopathic Pulmonary Fibrosis is classified as a rare
disease and presents a global commercial market that is forecast to
grow to US$8.8bn by 2027. Sales of standard-of-care therapies OFEV
and Esbriet achieved US$2.5bn and US$1bn respectively in 2021.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDZQLFLLQLLBBZ
(END) Dow Jones Newswires
June 27, 2022 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024